Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.

MLA

Kashyap, Manoj K., et al. “Ulocuplumab (BMS-936564 / MDX1338): A Fully Human Anti-CXCR4 Antibody Induces Cell Death in Chronic Lymphocytic Leukemia Mediated through a Reactive Oxygen Species-Dependent Pathway.” Oncotarget, vol. 7, no. 3, Jan. 2016, pp. 2809–22. EBSCOhost, https://doi.org/10.18632/oncotarget.6465.

APA

Kashyap, M. K., Kumar, D., Jones, H., Amaya-Chanaga, C. I., Choi, M. Y., Melo-Cardenas, J., Ale-Ali, A., Kuhne, M. R., Sabbatini, P., Cohen, L. J., Shelat, S. G., Rassenti, L. Z., Kipps, T. J., Cardarelli, P. M., & Castro, J. E. (2016). Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget, 7(3), 2809–2822. https://doi.org/10.18632/oncotarget.6465

Chicago

Kashyap, Manoj K, Deepak Kumar, Harrison Jones, Carlos I Amaya-Chanaga, Michael Y Choi, Johanna Melo-Cardenas, Amine Ale-Ali, et al. 2016. “Ulocuplumab (BMS-936564 / MDX1338): A Fully Human Anti-CXCR4 Antibody Induces Cell Death in Chronic Lymphocytic Leukemia Mediated through a Reactive Oxygen Species-Dependent Pathway.” Oncotarget 7 (3): 2809–22. doi:10.18632/oncotarget.6465.